Category - Developments

Developments

BeyondSpring to report positive Plinabulin CIN data at ASCO-SITC

BeyondSpring (NASDAQ: BYSI) announced new clinical results from its Study 106 program for lead asset Plinabulin, which demonstrates that combining Plinabulin with Neulasta not only improves overall efficacy for...

February 26, 2019

Developments

Titan Pharma in pact with AllianceRx Walgreens Prime to expand patient access to Probuphine

Titan Pharmaceuticals (NASDAQ:TTNP) entered a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime to expand patient access to its Probuphine six-month implant for the maintenance...

February 25, 2019

Developments

Eyenovia posts positive results from second MicroStat Phase 3 trial

Eyenovia (NASDAQ:EYEN) reported positive results from its second Phase 3 study, MIST-2, evaluating the safety and efficacy of its MicroStat fixed-combination formulation for the treatment of pharmacologic mydriasis, or...

February 25, 2019

Developments

ImmunoPrecise Antibodies receives subcontract for rabbit monoclonal antibodies

ImmunoPrecise Antibodies (TSXV:IPA; OTC:IPATF) has received a five-year subcontract from Leidos Biomedical Research, which operates the Frederick National Laboratory for Cancer Research for the NCI, to discover and...

February 21, 2019

Developments

Clearlake Capital-backed symplr to acquire API Healthcare

symplr, a leading healthcare governance, risk and compliance (GRC) software-as-a-service (SaaS) platform, backed by Clearlake Capital Group, has agreed to acquire API Healthcare, a leading provider of healthcare human...

February 20, 2019

Developments

BioSig reports successful first-in-human use of PURE EP system

BioSig Technologies (NASDAQ:BSGM) reported that it successfully conducted first patient cases using its PURE EP system at the Texas Cardiac Arrhythmia Institute in Austin, Tex. PURE EP is an FDA-approved cardiac signal...

February 20, 2019

Developments

Corindus seeking premarket clearance for CorPath GRX in neurovascular procedures

Corindus Vascular Robotics (NYSE American:CVRS) is seeking premarket clearance from the FDA to expand the use of the CorPath GRX System, a second-generation robotic platform, in neurovascular procedures. In 2016...

February 14, 2019

Developments

IntelGenx adds Douglas Mental Health University Institute to Montelukast VersaFilm trial sites

IntelGenx (TSXV:IGX; OTCQX:IGXT) plans to add Montreal’s Douglas Mental Health University Institute to its Montelukast VersaFilm Phase 2a clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD). World...

February 14, 2019

Developments

EyePoint Pharma secures debt facility of up to $60-million

EyePoint Pharmaceuticals (NASDAQ:EYPT) has secured a debt facility of up to $60-million from CR Group, a healthcare-focused investment firm, to retire existing debt and provide additional working capital to support...

February 13, 2019

Developments

Eyenovia expands MicroProst Phase 3 patient population for IOP lowering

Eyenovia (NASDAQ:EYEN) is expanding the patient population for its Phase 3 MicroProst program for the lowering of intraocular pressure (IOP). Following discussions with the FDA, the study population will include...

February 13, 2019

Category - Developments

BeyondSpring to report positive Plinabulin CIN data at ASCO-SITC

Titan Pharma in pact with AllianceRx Walgreens Prime to expand patient access to Probuphine

Eyenovia posts positive results from second MicroStat Phase 3 trial

ImmunoPrecise Antibodies receives subcontract for rabbit monoclonal antibodies

Clearlake Capital-backed symplr to acquire API Healthcare

BioSig reports successful first-in-human use of PURE EP system

Corindus seeking premarket clearance for CorPath GRX in neurovascular procedures

IntelGenx adds Douglas Mental Health University Institute to Montelukast VersaFilm trial sites

EyePoint Pharma secures debt facility of up to $60-million

Eyenovia expands MicroProst Phase 3 patient population for IOP lowering

General

More